Epidemiology of Monoclonal Gammopathies in Sub‐Saharan Africa: A Systematic Review and Meta‐Analysis of <scp>MGUS</scp> and Multiple Myeloma

MM and MGUS impose a substantial and under-recognised burden in SSA, with poorer survival outcomes compared with global averages. The high rates of delayed presentation, limited diagnostic capacity, absence of routine plasma cell disorder screening and restricted access to modern therapies likely contribute to the disparities observed. Strengthening diagnostic infrastructure and improving early detection and treatment pathways are urgently needed to advance equity in myeloma care across SSA.